title: Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
abstract: OBJECTIVE
  To evaluate the efficacy of intracameral tissue plasminogen activator (tPA) in the treatment of severe fibrinous membranes that do not respond to anti-inflammatory treatment.
  
  
  METHODS
  In this technique, 0.1 mL of aqueous was aspirated, followed by injection of 0.1 mL (25 microg) of tPA into the anterior chamber in 15 patients with severe fibrinous membranes that developed after pars plana vitrectomy (n = 6), cataract extraction (n = 4), combined cataract and glaucoma surgery (n = 2), trabeculectomy (n = 1), and endophthalmitis (n = 2). The clearance of fibrinous membranes and changes in visual acuity and in intraocular pressure were observed.
  
  
  RESULTS
  Patients were treated 2 to 10 days postoperatively (mean, 5.6 +/- 0.57 days). Complete fibrinolysis was observed in all cases. The mean time for clearance of fibrin was 7.73 +/- 2.73 hours. A temporary increase in intraocular pressure was noted in two cases.
  
  
  CONCLUSIONS
  In this technique, intracameral injection of 25 microg of tPA is both effective and safe in the treatment of severe fibrinous membranes that do not respond to anti-inflammatory treatment.
authors: Osmangazi University Medical Faculty, Department of Ophthalmology Eskisehir, Turkey.
authors: Nazmiye
authors: N
authors: Erol
authors: Ahmet
authors: A
authors: Ozer
authors: Seyhan
authors: S
authors: Topbas
authors: Nilgün
authors: N
authors: Yildirim
authors: Sumru
authors: S
authors: Yurdakul
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects* / Q000473:pathology; D018916:Blood-Aqueous Barrier; D005260:Female; D005337:Fibrin / Q000187:drug effects* / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000378:metabolism; D012008:Recurrence; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014792:Visual Acuity
chemical_list: D005343:Fibrinolytic Agents; D005337:Fibrin; D010959:Tissue Plasminogen Activator